Format

Send to

Choose Destination
J Alzheimers Dis. 2019;69(4):979-987. doi: 10.3233/JAD-190241.

Serum Insulin-Like Growth Factor I Deficiency Associates to Alzheimer's Disease Co-Morbidities.

Author information

1
Cajal Institute (CSIC), Madrid, Spain.
2
Universidad Nacional de San Agustín de Arequipa, Perú.
3
CIBERNED, Spain.
4
Department of Neurosciences, School of Medicine, UAM, Madrid, Spain.

Abstract

Increasing evidence supports the notion that Alzheimer's disease (AD), a condition that presents heterogeneous pathological disturbances, is also associated to perturbed metabolic function affecting insulin and insulin-like growth factor I (IGF-I). While impaired insulin activity leading to insulin resistance has been associated to AD, whether altered IGF-I function affects the disease is not entirely clear. Despite the limitations of mouse models to mimic AD pathology, we took advantage that serum IGF-I deficient mice (LID mice) present many functional perturbations present in AD, most prominently cognitive loss, which is reversed by treatment with systemic IGF-I. We analyzed whether these mice display other pathological traits that are usual co-morbidities of AD. We found that LID mice not only display cognitive disturbances, but also show altered mood and sociability, increased susceptibility to epileptiform activity, and a disturbed sleep/wake cycle. Collectively, these data suggest that reduced IGF-I activity contributes to heterogeneous deficits commonly associated to AD. We suggest that impaired IGF-I activity needs to be taken into consideration when modeling this condition.

KEYWORDS:

Alzheimer’s disease; animal models of disease; co-morbidities; insulin-like growth factor 1

PMID:
31156175
DOI:
10.3233/JAD-190241

Supplemental Content

Full text links

Icon for IOS Press
Loading ...
Support Center